The Principles of Engineering Immune Cells to Treat Cancer

Slides:



Advertisements
Similar presentations
Waging War on Cancer with the Sword of Immunity Cell Volume 158, Issue 2, (July 2014) DOI: /j.cell Copyright © 2014 Terms and Conditions.
Advertisements

Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
The Good Fat Cell Volume 147, Issue 7, (December 2011) DOI: /j.cell Copyright © 2011 Terms and Conditions Terms and Conditions.
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
The Principles of Engineering Immune Cells to Treat Cancer
Jacques F.A.P. Miller, Michel Sadelain  Cancer Cell 
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Research Techniques Made Simple: CAR T-Cell Therapy
Figure 1 Chimeric antigen receptor (CAR) structures
Volume 164, Issue 4, Pages (February 2016)
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial  Max Heckler, Stephanie.
Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?  Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,
Figure 1 CAR-T-cell design
Figure 2 Co-stimulatory receptors as immunomodulatory targets
Ada G. Blidner, Karina V. Mariño, Gabriel A. Rabinovich  Immunity 
Cell signaling and cancer
Tumor Evolution: A Problem of Histocompatibility
Colorectal cancer vaccines: Principles, results, and perspectives
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Nat. Rev. Urol. doi: /nrurol
Tipping the Balancing ACT
Volume 20, Issue 1, Pages (January 2017)
Daniel Abate-Daga, Marco L Davila  Molecular Therapy - Oncolytics 
Evolving Gene Therapy in Primary Immunodeficiency
Volume 20, Issue 6, Pages (June 2012)
Miki Ando, Hiromitsu Nakauchi  Experimental Hematology 
In This Issue Cell Volume 158, Issue 5, (August 2014)
DNA CLONING IN CANCER TREATMENT : GENE INFUSION (CAR-T Therapy)
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Volume 26, Issue 2, Pages (February 2018)
It’s a SMAD/SMAD World Cell
HIV Receives a “One Two Knockout Punch”
Pattern Recognition Receptors
Volume 152, Issue 1, (January 2013)
The Other Face of Chimeric Antigen Receptors
Volume 3, Issue 5, Pages (May 2003)
Engineering Stem Cell Organoids
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
Targeting Cancer Stemness in the Clinic: From Hype to Hope
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
Volume 130, Issue 6, (September 2007)
Quantitative Imaging Approaches to Study the CAR Immunological Synapse
Chung-Han Lee, Roman Yelensky, Karin Jooss, Timothy A. Chan 
Volume 20, Issue 6, Pages (June 2012)
Volume 143, Issue 6, (December 2010)
Shifting the Evolving CAR T Cell Platform into Higher Gear
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse  Saad S. Kenderian, David L. Porter,
Chimeric antigen receptor T-cell therapy for solid tumors
Not Just Any T Cell Receptor Will Do
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Volume 24, Issue 2, Pages (February 2016)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Genetically modified TCRs for cancer immunotherapy.
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Therapy of Alopecia Areata: On the Cusp and in the Future
Releasing the Brakes on Cancer Immunotherapy
Padmanee Sharma, James P. Allison  Cell 
Volume 163, Issue 4, (November 2015)
Volume 163, Issue 2, (October 2015)
Fig. 1 Engineered T cells: design of TCR versus CAR T cells.
CAR T cell immunotherapy for human cancer
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Volume 134, Issue 6, (September 2008)
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
In This Issue Cell Volume 145, Issue 3, (April 2011)
Volume 148, Issue 1, (January 2012)
Presentation transcript:

The Principles of Engineering Immune Cells to Treat Cancer Wendell A. Lim, Carl H. June  Cell  Volume 168, Issue 4, Pages 724-740 (February 2017) DOI: 10.1016/j.cell.2017.01.016 Copyright © 2017 Terms and Conditions

Figure 1 Engineered Therapeutic T Cells Provide a Transformative New Platform for Interfacing with Complex Diseases such as Cancer Therapeutic T cells combine elements of more traditional therapeutic approaches to yield an integrated smart sense-and-response agent. The emerging field of synthetic biology is providing tools and approaches to program therapeutic cells in diverse ways. Cell 2017 168, 724-740DOI: (10.1016/j.cell.2017.01.016) Copyright © 2017 Terms and Conditions

Figure 2 Platforms for Redirecting T Cells to Cancer (A) T cell receptors (e.g., anti-NY-ESO1) or chimeric antigen receptors (e.g., anti-CD19 CAR). (B) CAR structure includes an extracellular antigen recognition domain fused to intracellular TCR signaling domains (CD3z) and co-stimulatory domains (e.g., CD28 or 4-1BB). (C) Current status of CD19 CAR therapies. (D) Current status of engineered T cells directed toward solid tumors. Cell 2017 168, 724-740DOI: (10.1016/j.cell.2017.01.016) Copyright © 2017 Terms and Conditions

Figure 3 Functional Needs for Optimal Anti-cancer T Cell Therapy (A) Five major functional challenges for a therapeutic T cell. (B) Breaking down how, when, and where these five challenges arise as a therapeutic T cell interacts with cancer. (C) Diagram of different types of therapeutic T cells and how well they address these five challenges. The distance of points from the center indicate how effective a cell is at addressing a particular challenge. The overlaid plots trace early generations of CAR T cells, as well as ongoing and projected next-generation improvements. Cell 2017 168, 724-740DOI: (10.1016/j.cell.2017.01.016) Copyright © 2017 Terms and Conditions

Figure 4 Emerging New Engineering Solutions for Addressing the Functional Challenges of Anti-cancer T Cells (A–D) New molecular tools for improving therapeutic T cell tumor recognition (A), proliferation and persistence (B), remodeling of the tumor microenvironment (C), and control (D). Cell 2017 168, 724-740DOI: (10.1016/j.cell.2017.01.016) Copyright © 2017 Terms and Conditions

Figure 5 Smart Cell Therapies May Fulfill Promise of Precision Medicine (A) The design and implementation of therapeutic immune cells will, in principle, combine tumor informatics with systems and synthetic biology to construct cell therapies strategically optimized to recognize discriminating features and to attack tumor vulnerabilities. (B) The emerging synthetic biology toolkit for cell engineering may allow modular construction of precision therapeutic programs (here modeled by an illustrative program inspired by the Scratch graphical programming language). (C) Precision informatics combined with custom engineered therapeutic cells has the potential to provide true precision therapies. Cell 2017 168, 724-740DOI: (10.1016/j.cell.2017.01.016) Copyright © 2017 Terms and Conditions